| Literature DB >> 33195402 |
Muhammad Waqas1, Ali Haider1, Muhammad Sufyan1, Sami Siraj2, Sheikh Arslan Sehgal1,3.
Abstract
Coronaviruses (CoVs) belong to the Coronaviridae-family. The genus Beta-coronaviruses, are enveloped positive strand RNA viruses with club-like spikes at the surface with a unique replication process and a large RNA genome (∼25 kb). CoVs are known as one of the major pathogenic viruses causing a variety of diseases in birds and mammals including humans (lethal respiratory dysfunctions). Recently, a new strain of coronavirus has been identified and named as SARS-CoV-2. A large number of COVID-19 (disease caused by SARS-CoV-2) cases are being diagnosed all over the World especially in China (Wuhan). COVID-19 showed high mortality rate exponentially, however, not even a single effective cure is being introduced yet against COVID-19. In the current study, immunoinformatics approaches were employed to predict the antigenic epitopes against COVID-19 for the development of a coronavirus peptide vaccine. Cytotoxic T-lymphocyte (CTL) and B-cell epitopes were predicted for SARS-CoV-2 coronavirus structural proteins (Spikes, Membrane, Envelope, and Nucleocapsid). The docking complexes of the top 10 epitopes having antigenic sites were analyzed led by binding affinity and binding interactional analyses of top ranked predicted peptides with the MHC-I HLA molecule. The predicted peptides may have potential to be used as peptide vaccine against COVID-19.Entities:
Keywords: SARS-CoV; SARS-CoV-2; corona virus disease 2019; immunoinformatics; peptide vaccines
Year: 2020 PMID: 33195402 PMCID: PMC7593713 DOI: 10.3389/fmolb.2020.00227
Source DB: PubMed Journal: Front Mol Biosci ISSN: 2296-889X
FIGURE 1Schematic workflow for the prediction of peptide based vaccine against SARS-CoV-2.
Predicted CTL epitopes from the SARS-CoV-2 structural proteins having antigenic sites.
| Residue number | Peptide sequence | Predicted MHC binding affinity | Rescale binding affinity | C-terminal cleavage affinity | TAP transport efficiency | Prediction score |
| 865 | LTDEMIAQY | 0.7953 | 3.3768 | 0.9723 | 2.779 | 3.6616 |
| 258 | WTAGAAAYY | 0.6735 | 2.8596 | 0.7339 | 2.863 | 3.1128 |
| 604 | TSNQVAVLY | 0.6559 | 2.7847 | 0.944 | 2.991 | 3.0758 |
| 361 | CVADYSVLY | 0.5348 | 2.2705 | 0.9764 | 3.18 | 2.5759 |
| 733 | KTSVDCTMY | 0.4908 | 2.084 | 0.9649 | 3.016 | 2.3795 |
| 746 | STECSNLLL | 0.5136 | 2.1808 | 0.8879 | 0.703 | 2.3492 |
| 213 | SSDNIALLV | 0.6531 | 2.7729 | 0.9682 | 0.286 | 2.9325 |
| 171 | ATSRTLSYY | 0.5463 | 2.3195 | 0.9375 | 3.09 | 2.6146 |
| 34 | LTALRLCAY | 0.5594 | 2.3 | 0.672 | 2.933 | 2.6158 |
| 104 | LSPRWYFYY | 0.4837 | 2.0538 | 0.9746 | 2.815 | 2.3408 |
The maximum and minimum values of the predicted peptides.
| Protein | Length | Molecular Weight (g/mol) | Hydropathicity | Theoretical PI | Max. surface accessibility (%) | Min. surface accessibility (%) | Max. Flexibility (%) | Min. Flexibility (%) | Max. Antigenicity (%) | Min. Antigenicity (%) |
| Membrane | 222 | 25146.6 | 0.446 | 9.51 | 5.199 | 0.078 | 8.7 | 0.061 | 7.6 | 0.01 |
| Envelope | 75 | 83650.4 | 1.128 | 8.57 | 4.136 | 0.088 | 6.53 | 0.005 | 7.5 | 0.002 |
| Nucleocapsid | 419 | 45625.7 | −0.971 | 10.07 | 6.966 | 0.05 | 8.8 | 0.052 | 6.925 | 0.05 |
| Spikes | 1273 | 141178 | −0.079 | 6.24 | 6.051 | 0.07 | 5.7 | 0.3 | 6.121 | 0.0751 |
Top ranked selected discontinues epitopes, interacting residues and scores.
| Sr. No. | Residues | Number of residues | Score |
| 1 | A:G11, A:K12, A:G15, A:C16, A:C22, A:G23, A:T24, A:W31, A:D33, A:D34, A:R40, A:C44, A:T45, A:S46, A:E47, A:D48, A:M49, A:L50, A:N51, A:P52, A:N53, A:Y54, A:E55, A:D56, A:L57, A:L58, A:I59, A:R60, A:K61, A:S62, A:N63, A:H64, A:N65, A:L67, A:Q69, A:A70, A:G71, A:N72, A:V73, A:Q74, A:L75, A:R76, A:V77, A:I78, A:G79, A:H80, A:S81, A:M82, A:K90, A:V91, A:D92, A:T93, A:A94, A:N95, A:P96, A:K97, A:T98, A:P99, A:K100, A:N133, A:D155, A:C156, A:G183, A:P184, A:F185, A:V186, A:D187, A:R188, A:Q189, A:T190, A:A191, A:Q192, A:A193, A:A194, A:G195, A:T196, A:D197 | 77 | 0.706 |
| 2 | A:S1, A:G2, A:F3, A:T198, A:T199, A:V212, A:I213, A:N214, A:G215, A:D216, A:R217, A:W218, A:F219, A:L220, A:N221, A:R222, A:F223, A:T224, A:T225, A:T226, A:L227, A:N228, A:D229, A:F230, A:N231, A:L232, A:V233, A:A234, A:M235, A:K236, A:Y237, A:N238, A:Y239, A:E240, A:P241, A:L242, A:T243, A:Q244, A:D245, A:V247, A:D248, A:G251, A:P252, A:S254, A:A255, A:Q256, A:T257, A:G258, A:I259, A:A260, A:V261, A:L262, A:D263, A:A266, A:S267, A:K269, A:E270, A:L271, A:L272, A:Q273, A:N274, A:G275, A:M276, A:N277, A:G278, A:R279, A:T280, A:I281, A:L282, A:G283, A:S284, A:A285, A:L286, A:S301, A:G302, A:V303, A:T304, A:F305, A:Q306 | 79 | 0.703 |
The designed peptides against SARS-CoV-2 peptides-MHC class I HLA-B interactions.
| Peptide | Global energy (kcal/mol) | Attractive VdW energy (kcal/mol) | H bond Energy (kcal/mol) | Peptide-MHC pair | Bond distance (Å) | Conserved residues |
| LTDEMIAQY | −34.23 | −26.46 | −1.11 | ILE 6 CD ALA 69.A CB | 2.400 | TYR9 |
| TYR 9 CB GLN 70.A OE1 | 2.306 | ARG62 | ||||
| ILE 6 CD ALA 69.A HB3 | 1.855 | ILE66 | ||||
| TYR 9 O1 GLN 70.A HE22 | 1.458 | THR73 | ||||
| MET 5 CE ARG 62.A NH1.B | 2.738 | TYR99 | ||||
| TYR 9 O1 GLN 70.A NE2 | 2.350 | GLU152 | ||||
| GLN 8 NE2 GLN 155.A C | 2.604 | |||||
| WTAGAAAYY | −45.23 | −26.05 | −0.50 | TYR 9 CB ALA 158.A CB | 2.123 | TYR9 |
| TRP 1 CZ3 ARG 62.A NH2.B | 2.064 | ARG62 | ||||
| GLY 4 CA ILE 66.A CD1 | 3.964 | ILE66 | ||||
| TRP 1 CD1 TYR 7.A CD2 | 3.846 | THR73 | ||||
| TRP 1 CE2 ASN 63.A CB | 3.797 | TYR99 | ||||
| ALA 5 CB TYR 159.A HD2 | 3.278 | GLU152 | ||||
| TSNQVAVLY | −49.99 | −26.52 | −0.67 | LEU 8 CD2 TYR 99.A CZ | 2.524 | TYR9 |
| GLN 4 NE2 ARG 62.A HE.B | 1.596 | ARG62 | ||||
| GLN 4 NE2 ARG 62.A NH1.B | 2.223 | ILE66 | ||||
| LEU 8 CD2 TYR 99.A OH | 2.339 | THR73 | ||||
| LEU 8 CD2 TYR 99.A CE2 | 2.564 | TYR99 | ||||
| GLU152 | ||||||
| SSDNIALLV | −40.24 | −22.14 | −1.32 | LEU 8 CA ILE 66.A CG2 | 3.963 | TYR9 |
| VAL 9 CG2 ARG 156.A NE | 3.890 | ARG62 | ||||
| LEU 7 CB ILE 66.A HG13 | 3.269 | ILE66 | ||||
| LEU 8 CD2 ILE 66.A C | 3.971 | THR73 | ||||
| ALA 6 CA TYR 159.A CB | 3.973 | TYR99 | ||||
| ASP 3 C GLU 163.A CD | 3.799 | GLU152 | ||||
| ASP 3 C ARG 62.A CZ.B | 3.800 | |||||
| LTALRLCAY | −53.65 | −26.02 | −1.97 | THR 2 CB GLN 70.A NE2 | 3.881 | TYR9 |
| THR 2 CG2 ALA 69.A CB | 3.958 | ARG62 | ||||
| CYS 7 SG ARG 62.A NH2.B | 3.773 | ILE66 | ||||
| LEU 1 CG TYR 116.A OH | 3.763 | THR73 | ||||
| TYR 9 CE2 GLN 155.A OE1 | 3.625 | TYR99 | ||||
| LEU 4 CD1 ASP 114.A CG | 3.969 | GLU152 | ||||
| ALA 3 CB GLN 70.A OE1 | 3.749 | |||||
| ATSRTLSYY | −48.57 | −27.52 | −1.18 | SER 6 CA ILE 66.A HG22 | 3.258 | TYR9 |
| TYR 9 O1 GLN 70.A HE22 | 2.865 | ARG62 | ||||
| TYR 9 CB TYR 99.A CG | 3.970 | ILE66 | ||||
| TYR 9 CD1 ARG 156.A HH12 | 3.150 | THR73 | ||||
| VAL 2 CA ARG 62.A HH22.B | 3.271 | TYR99 | ||||
| TYR 9 CZ ARG 156.A CA | 3.796 | GLU152 | ||||
| TYR 5 OH TYR 159.A CA | 3.556 | |||||
| CVADYSVLY | −38.79 | −25.19 | −2.05 | THR 5 CG2 ARG 156.A CZ | 3.943 | TYR9 |
| ALA 1 N ALA 158.A HB3 | 3.004 | ARG62 | ||||
| TYR 9 CE2 TRP 147.A CH2 | 3.829 | ILE66 | ||||
| TYR 9 O1 TYR 9.A CE2 | 3.551 | THR73 | ||||
| ALA 1 CB GLN 155.A NE2 | 3.876 | TYR99 | ||||
| TYR 9 CE1 ARG 156.A HH21 | 3.136 | GLU152 | ||||
| ALA 1 CA GLN 155.A CG | 3.956 | |||||
| KTSVDCTMY | −27.73 | −21.80 | −2.62 | LYS 1 CE GLN 70.A OE1 | 3.721 | TYR9 |
| TYR 9 O2 THR 73.A CG2 | 3.542 | ARG62 | ||||
| MET 8 CE ARG 156.A NE | 3.876 | ILE66 | ||||
| VAL 4 CG1 ILE 66.A H | 3.254 | THR73 | ||||
| THR 2 CG2 TYR 159.A CG | 3.968 | TYR99 | ||||
| VAL 4 CG2 ILE 66.A HG23 | 3.273 | GLU152 | ||||
| VAL 4 CA ILE 66.A HG12 | 3.274 | |||||
| STECSNLLL | −45.10 | −24.24 | −2.18 | SER 5 CA ARG 156.A CD | 3.956 | TYR9 |
| LEU 7 CD1 ALA 69.A CB | 3.961 | ARG62 | ||||
| CYS 4 CB GLU 152.A OE2 | 3.745 | ILE66 | ||||
| SER 1 OG ALA 150.A C | 3.547 | THR73 | ||||
| LEU 9 CB TYR 159.A CE1 | 3.967 | TYR99 | ||||
| SER 5 CA ARG 156.A HE | 3.276 | GLU152 | ||||
| LEU 7 CD1 GLN 70.A CA | 3.977 | |||||
| LSPRWYFYY | −25.01 | −24.40 | −3.75 | TYR 8 CE1 TYR 9.A OH | 3.636 | TYR9 |
| TRP 5 CB GLN 155.A C | 3.962 | ARG62 | ||||
| TYR 9 C ARG 62.A HH11.B | 3.082 | ILE66 | ||||
| PHE 7 CA ILE 66.A CD1 | 3.963 | THR73 | ||||
| LEU 1 CD1 GLN 155.A CG | 3.965 | TYR99 | ||||
| PHE 7 O ILE 66.A CD1 | 3.568 | GLU152 | ||||
| TRP 5 CE3 GLN 155.A CB | 3.857 |
FIGURE 2Peptide-MHC class I HLA-B (pink color helices denotes the conserved binding domain of HLA-B and the remaining protein structure is presented in the wire shape), binding interacting residues of the top-ranked 10 peptides represented in different colors, 6 spike peptides brown color residues, 2 membrane peptides red color residues, 1 nucleocapsid, and 1 envelope peptide with purple and blue color residues, respectively.